ClariVital HealthFront DeskBook a demo

In research

Cancer Research Workbench

A BrightWeb Solutions research prototype that compares how one amino-acid change affects predicted HLA binding.

In personalized cancer-vaccine research, a short peptide from a tumor mutation must bind to an HLA protein for that protein to present it to T cells. The workbench isolates that binding-prediction step.

It uses the pretrained MHCflurry 2.3.28 model to compare each variant with its reference across three HLA alleles and exports the results with the model version.

Research only. No clinical validation. Not a diagnostic test. Not for medical use.

These are computational predictions on synthetic inputs. Whether a peptide occurs in a tumor, provokes an immune response, or helps a patient requires separate evidence.

See the workbench and join the waitlist

In research. Joining the waitlist is free.

Example peptide pair · D5N

Reference
ALYQDVKLV
Variant
ALYQNVKLV
HLA-A*02:01 predicted affinity (nM)Lower values indicate stronger predicted binding.
PairReferenceVariant
C01 · D5N34.443.2
C02 · Q4R12.113.1
C03 · I6V8.910.2
C04 · K7R59.860.9
C05 · A5V27.623.1
C06 · Q5N13.713.8
Research example · Synthetic peptide pairs · Not a clinical result